Magnicor is effective and safe domestic drug for prophylaxis of cardiovascular diseases
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Data about pathogenetically justification of use, efficiency and safety of acetylsalicylic acid as antiplatelet agents in cardiology practice are analysed in the article. The article contains short analysis of the domestic market of acetylsalicylic acid preparations, that are used in cardiology practice. The article also contains recommendation of practical character for optimization of choice of acetylsalicylic acid preparations. The authors of the article pay great attention to the analysis of data about influence of medicinal form of acetylsalicylic acid preparations and composition of the combined preparations that contain it on pharmacokinetic parameters and profile of their safety. Based on these data the authors of the article come to the conclusion that one of the most safe and effective preparations of acetylsalicylic acid that is presented today at the market of Ukraine there is Magnicor.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Аспирин кардио в энтеросолюбильной оболочке. Антитромбоцитарная терапия ацетилсалициловой кислотой / Под ред. М.Я. Руды. – Универсум Паблишинг, 1998. – 220 с.
Баркаган З.С., Момот А.П., Котовщикова Е.Ф., Шилова А.Н. Выбор препаратов и мониторинг эффективности антитромботических средств. Материалы научнопрактической конференции «Острый коронарный синдром: проблемы патогенеза, профилактики, диагностики, классификации, терапии» 22–23 марта 2001. Томск; 2001. – С. 192–194.
Безопасность и фармакоэкономическая эффективность применения различных препаратов ацетилсалициловой кислоты у пациентов с ИБС / Верткин А.Л., Аристархова О.Ю., Адонина Е.В. и соавт. // Русский медицинский журнал http://www.rmj.ru
Державний формуляр лікарських засобів / Під редакцією В.Т. Чумака, В.І. Мальцева, А.М. Морозова, В.Д. Парія, А.В. Степаненко. Вип. 2. – К., 2010. – 845 с.
Довідник лікарських засобів України 2010 / За ред. В.Т. Чумака // http://www.pharma-center.kiev.ua/view/dov
Князева С.А., Мельник М.В., Шилов А.М. Антиагреганты в практике профилактики и лечения коронарных болезней сердца // http://www.rmj.ru
Князева С.А., Шилов А.М. Ацетилсалициловая кислота – нестероидный противовоспалительный препарат как антиагрегант в практике лечения сердечнососудистых заболеваний // http://www.rmj.ru
Компендиум 2009 – лекарственные препараты. В 2х томах /Под ред. В.Н. Коваленко, А.П. Викторова – К..: Морион, 2009. – 2224 с.
Конорев М.Р. Выбор оптимального антацидного препарата в клинической практике // Consilium Medicum. – 2003. – Т. 05, № 10. – Приложение Гастроэнтерология. http://www.Consilium-Medicum.htm
Лагута П.С. Вопросы применения ацетилсалициловой кислоты в клинической практике: эффективность и безопасность // Русский медицинский журнал. – 2005. – Т. 13, № 19. – С. 1241–1245.
Маалокс в лечении НПВПассоциированных гастропатий / Кательницкая Л.И., Лужецкая И.В., Голиусова С.А. и соавт. // Современные аспекты антацидной терапии. Маалокс в клинической практике / Под ред. О.Н. Минушкина. – М., 1998. – С. 51–53.
Минушкин О.Н. Антацидные средства в лечении гастроэзофагеальной рефлюксной болезни // Фарматека. – 2007. – № 6. – С. 44–47.
Ольбинская Л.И., Гофман А.М. Лечение и профилактика тромбозов. – М.: Вагриус, 2000. – 196 с.
Регистр лекарственных средств России. Энциклопедия лекарств. – М.: «РЛС2008», 2007. – Вып. 16. – 1456 с.
Современные аспекты антацидной терапии. Маалокс в клинической практике / Под ред. О.Н. Минушкина. – М., 1998. – 59 с.
Шварц Г.Я., Сюбаев Р.Д. Методические указания по изучению новых нестероидных противовоспалительных препаратов // Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. – М., 2000. – С. 234–241.
Эпидемиологические аспекты сердечнососудистых заболеваний http://medbe.ru/materials/obshchee/epidemiologicheskieaspektyserdechnososudistykhzabolevaniy/medbe.ru
Antacids. Today’s drugs // Br. Med. J. – 1970. – Vol. 3. – P. 35–36.
Aspirin ein Jahrhundertpharmakon Leverkusen, 1983. – 84 s.
Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial / Cairns J.A., Gent M., Singer J. et al // N. Engl. J. Med. – 1985. – Vol. 313. – P. 1369–1375.
Awtry E.H., Loscalzo J. Aspirin // Circulation. – 2000. – Vol. 101. – P. 1206–1218.
Canner P.L. Aspirin in coronary heart disease. Comparison of six clinical trials // Israel J. Med. Sci. – 1983. – Vol. 19. – P. 413–423.
Canner P.L. Aspirin in coronary heart disease. Comparison of six clinical trials // Israel J. Med. Sci. – 1983. – Vol. 19. – P. 413–423.
Cipollone F., Rocca B., Patrono C. Cyclooxygenase2 expression and inhibition in atherothrombosis // Arterioscler. Thromb. Vasc. Biol. – 2004. – Vol. 24. – P. 246–255.
Clinical pharmacology of platelet cyclooxygenase inhibition / Patrono C., Ciabattoni G., Patrignani P. et al // Circulation. – 1985. – Vol. 72. – P. 1177–1184.
Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists’ Collaboration // BMJ. 2002. – Vol. 324. – P. 71–86.
Cox D., Maree A.O., Dooley M. et al. Effect of enteric coating on antiplatelet activity of lowdose aspirin in healthy volunteers // Stroke. – 2006. – № 37. – Р. 2153–2158
Craven L.L. Acetylsalicylic acid, possibli prevention of coronary thrombosis // Ann. West. Med. Surg. – 1950. – Vol. 4. – P. 95–96.
Dajani E.L., Agrawal N.M. Protective effects of prostaglandins against nonsteroidal antiinflammatory druginduced dastrointestinal mucosal injury // Int. J. Clin. Pharm. Res. – 1989. – Vol. 9, № 6. – P. 359–369.
Differential effects of two doses of aspirin on plateletvessel wall interaction in vivo / Wu K.K., Chen Y.C., Fordham E. et al // J. Clin. Invest. – 1981. – Vol. 68, № 2. – P. 382–387.
Doubleblind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris / JuulMöller S., Edvardsson N., Jahnmatz B. et al [Swedish Angina Pectoris Aspirin Trial (SAPAT) Group] // Lancet. – 1992. – Vol. 340. – P. 1421–1425
Effect of antacid and H2receptor blocker treatment on gastric endocrine cells / Arnold R., Garbe I., Koop H. et al // Scand. J. Gastroenterol. Suppl. – 1984. – Vol. 101. – P. 31–37.
Effect of antacid treatment on endogenous prostaglandin synthesis in human antral and duodenal mucosa / Preclik G, Stange E.F., Gerber K. et al // Dig. Dis. Sci. – 1989. – Vol. 34 (12). – P. 1860–1864.
Elwood P.C. Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction // Br. Med. J. – 1981. – Vol. 282. – P. 481–483.
Gafni Y., Schwartban M., Raz A. In vivo inhibition of PG biosynthesis by antiinflammatory drugs: differential effects of aspirin, indomethacin and maclofenamic acid on PGbiosynthesis in rabbit and rat kidney. (Abstract) // Prostaglandins. – 1976. – Vol. 11, № 3. – P. 474.
ISIS2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS2 // Lancet. – 1988. – Vol. 2. – P. 349–360.
ISIS3 (Third International Study of Infarct Survival) Collaborative Group: ISIS3: randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction // Lancet. – 1992. – Vol. 339. – P. 753–770.
Klimt C.R., Knatterud G.L., Stamler H. Persantinaspirin reinfarction study. Part II: secondary prevention with persantin and aspirin // J. Am. Coll. Cardiol. – 1986. – Vol. 7. – P. 251–269.
Kuwayama H., Matsyo Y., Eastwood G.L. Gastroduodenal mucosal injury by nonsteroidal antiinflammatory drugs // Drug Invest. – 1990. – Vol. 2. – Suppl. № 1. – P. 22–26.
Lowdose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxanerelated platelet function / De Caterina R., Giannessi D., Bernini W. et al // Eur. Heart J. – 1985. – Vol. 6. – P. 409–417.
Martindal. The Complete Drug Reference. – London: Pharmaceutical Press, 2009. – 3694 p.
Meijer A., Werter C.J., Verheugt F.W.A. The APRICOT study: Coumadin versus aspirin in the prevention of reocclusion after successful thrombolysis, a prospective, placebocontrolled angiographic study // Circulation. – 1991. – Vol. 84, Suppl II. – P. 571.
Nietsch P. Therapeutic application of aspirin. – Germany, 1989. – 75 p.
Patrono C., Coller B., Dalen J.E. et al. Plateletactive drugs: the relationships among dose, effectiveness, and side effects // Chest. 2001. – № 119. – Р. 39S–63S.
Peto R. Aspirin after myocardial infarction // Lancet. – 1980. – P. 1172–1173.
Rainsford K.D., Brune K. Selective cytotoxic actions of aspirin on parietal cells: a principal factor in the early stages of aspirininduced gastric damage // Arch. Toxicol. – 1978. – Vol. 40. – P. 143–150.
Randomised trial of prophylactic daily aspirin in British male doctors / Peto R., Gray R., Collins R. et al // Br. J. Med. – 1988. – Vol. 296. – P. 313–316.
Roth G.J., Siok C.J. Acetylation of the NH2terminal serine of prostaglandinsynthetase by aspirin // J. Biol. Chem. – 1978. – Vol. 253. – P. 3782–3784.
Sagar K.A., Smyth M.R. A comparative bioavailability study of different aspirin formulations using online multidimensional chromatography // J. Pharm. Biomed. Anal. – 1999. – Vol. 21. – P. 383–392.
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa / Whittle B.J.R., Higgs G.A., Eakins C.E. et al // Nature. – 1980. – Vol. 280. – P. 271–273.
Siel D., Griffin J., Andrews D.S. Plasma aspirin esterase activity: relationship to aspirin ingestion and peptic ulceration // Aust. N.Z.J.Med. – 1985. – Vol. 15. – P. 562.
Steering Committee of the Physicians’ Health Study Research Group: Preliminary report: findings from the aspirin component of the ongoing physicians’ health study // N. Engl. J. Med. – 1989. – Vol. 321. – P. 129–135.
Vandvik O, Lincoff AM. et al. Primary and secondary prevention of cardiovascular disease. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest, 2012;141 (2):637s668s.
Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs // Nature. – 1971. – Vol. 231. – P. 232–253.
